logo ct-atlantic

company

Team

Strategy

Research_and_Devolpment

Scientific background

Technology Platform

Products

Media

Careers

Contact

 

microscope

While cancer still is a life-threatening and often deadly disease, some people experience stable disease for a long time or even spontaneous remissions of their cancer.

Based on selected clinical data, the company's hypothesis is that at least some of these cancer patients harbor antibodies that have been created and optimized by their immune system to the extent that they are highly efficacious and have contributed to the stabilization of the cancer.

Through the selection of the correct patient material (conducted under patient approval and standards set forth and approved by the relevant ethics committees), CT Atlantic utilizes its proprietary technology platform – BCDtech™, to identify antibodies that are:
(i) Non-toxic and
(ii) Potentially related to the positive clinical course.